Biotech & Biopharmaceuticals
Research-stage and commercial biotechnology companies developing large molecule therapeutics, cell and gene therapies, and novel biological treatments for disease.
- 5
- Verticals
Overview
Biotech & Biopharmaceuticals covers research-stage and commercial companies developing small-molecule, large-molecule, cell, and gene therapies. It is the innovation engine of healthcare — high-risk, high-reward, R&D-intensive, and the source of the industry's growth — spanning big pharma, mid-cap biopharma, and a vast emerging-biotech ecosystem.
M&A is structural and constant: big pharma faces a wave of patent cliffs (loss of exclusivity on major drugs) and acquires biotech to replenish pipelines, while the GLP-1/obesity franchise (Novo Nordisk, Eli Lilly) has reshaped the sector's growth and valuations. U.S. manufacturing receipts understate the global, IP-driven economics.
Market snapshot
- Market size
- ~$211B
- Growth
- ~1.4%CAGR (2017–22, nominal)
- Companies
- ~2,181 firms
58.2% of firms have fewer than 20 employees: 1,269 micro-businesses, below most mandates.
- 20–99
- 40344%
- 100–499
- 26829%
- 500+
- 24126%
U.S. biopharma manufacturing — ~2,180 firms, extraordinarily asset- and IP-heavy (payroll just 13% of revenue, ~$97M revenue per firm). The ~$211B is U.S. manufacturing receipts; the global, patent-driven market is far larger. Measured growth was slow (~1.4%/yr) because the value sits in IP and pipeline, not domestic production volume — while M&A runs hot, driven by patent cliffs and the GLP-1 boom.
NAICS 325411, 325412, 325414. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.
Business model & economics
Revenue model
Patent-protected drug sales and royalties
Key economics
- Revenue per firm
- $96,794,531
- Revenue per employee
- $804,188
- Employees per firm
- 125.3
- Recurring revenue
- Moderate
- EBITDA margin
- High for branded on-patent drugs
- Capex intensity
- High
on-patent franchises; cliffs reset it
Characteristics
- Scale-driven — payroll is only 13% of revenue; the cost base is assets, not headcount
- Deep strategic-buyer pool — 241 firms exceed 500 employees, so a scaled asset has trade buyers
- The innovation engine of healthcare — high-risk, R&D-intensive.
- Patent cliffs drive constant pipeline-replenishing M&A.
- GLP-1/obesity franchise reshaped sector growth.
NAICS 325411, 325412, 325414. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.
Geographic concentration
Biotech and biopharmaceutical operations concentrate in the established life-sciences clusters — California (the Bay Area and San Diego), Massachusetts (Greater Boston), and North Carolina's Research Triangle — by far the largest centers of industry employment.
U.S. Census Bureau — 2022 County Business Patterns (employment by state), NAICS 325411/325412/325414. Leading states by biopharmaceutical employment.
M&A deal context
Who’s acquiring
- Big pharma & biopharma strategics
- Biotech-acquiring platforms
- VC- and crossover-backed biotech
What’s driving deals
- Patent-cliff-driven acquisition of biotech pipelines.
- GLP-1 and novel-modality competition.
- Biotech funding cycles and platform deals.
Verticals in this segment
Find Biotech & Biopharmaceuticals acquisition targets
Search Acquisera’s index for companies classified under Biotech & Biopharmaceuticals (4.9.1) and build a targeted deal pipeline.
Search companies